6 Stocks Poised For Potential Acquisition In The Next 12 Months, According To Goldman Sachs, Including A 200% YTD Gainer - ( AACT ) , Walt Disney ( NYSE:DIS )
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. The bank reported that the total dollar value of M&A deals has risen 29% year-over-year, with deal volumes in 2025 climbing 8%. The bank projects an additional 15% increase in new ...
3 Reasons to Buy Novo Nordisk Stock Right Now
The pharmaceutical leader is gradually laying the groundwork for a strong rebound.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on September ...
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday - Adobe ( NASDAQ:ADBE ) , C3.ai ( NYSE:AI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised C3.ai, Inc. AI price target from $16 to $17. UBS analyst Radi Sultan maintained a Neutral rating.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on September ...
Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk's Wegovy in MASH, According to Spherix Global Insights
EXTON, PA, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- The recent approval of Novo Nordisk's Wegovy ( semaglutide 2.4mg ) as the second treatment for metabolic dysfunction-associated steatohepatitis ( MASH ) represents a critical step forward in a condition with a vast patient population and significant ...
Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Gyre Therapeutics ( NASDAQ:GYRE )
HC Wainwright initiates Gyre with a Buy rating and $18 price target. Hydronidone is projected to reach $6 billion in annual U.S. sales by 2033. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 )
CONSHOHOCKEN, Pa., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it granted equity awards on August 15, ...
The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know
The famous medicine continues its impressive march forward.
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Madrigal Receives European Commission Approval for Rezdiffra™ ( resmetirom ) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., Aug. 19, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that the European Commission ( EC ) has ...
NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain
NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend.
What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk ( NYSE:NVO )
36.8% on Wegovy showed liver fibrosis improvement vs 22.4% on placebo at week 72. FDA approval adds MASH with liver fibrosis to Wegovy's indications. Get more market-moving news first with AI-powered analysis that turns noise into opportunity. On Saturday, the U.S.
Billionaire Investor Buys Google And This Gold Miner Stock - Perpetua Resources ( NASDAQ:PPTA )
John Paulson's hedge fund, Paulson & Co., discloses the purchase of 9,000 shares of Alphabet. The also increases its position in gold miner Perpetua Resources. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing.
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal ( MDGL ) Q2 Revenue Soars 1,313%
Madrigal Pharmaceuticals ( NASDAQ:MDGL ) , a biopharmaceutical firm focused on liver diseases, reported its second quarter 2025 earnings on August 5, 2025. The standout news in this release was an explosive surge in GAAP revenue to $212.8 million, sharply exceeding the consensus estimate of ...
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Second-quarter 2025 Rezdiffra™ ( resmetirom ) net sales of $212.8 million As of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, 2045 Announced global licensing agreement for an oral GLP-1 development candidate
Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports second-quarter 2025 financial results and ...
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
CONSHOHOCKEN, Pa., July 30, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) ( "Madrigal" ) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited ( HKEX Stock CodeL 1093 ) ( "CSPC" ) for SYH2086, a ...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025
CONSHOHOCKEN, Pa., July 25, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , announced today that it will release its second-quarter ...
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and Host Webcast on August 5, 2025 - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., July 25, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
CONSHOHOCKEN, Pa., July 22, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that it has entered into a $500 million ...
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Madrigal's Fatty Liver Disease Drug Gets Recommendation - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CHMP recommends conditional EU approval of Rezdiffra for noncirrhotic MASH with fibrosis. Two-year data show 51% of patients had ≥25% improvement in liver stiffness. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.
Madrigal Receives Positive CHMP Opinion for Resmetirom ( Rezdiffra™ ) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
CONSHOHOCKEN, Pa., June 20, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced that the Committee for Medicinal Products ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., June 17, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., June 02, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT.
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions - Aardvark Therapeutics ( NASDAQ:AARD )
Timothy Kieffer, Ph.D., appointed Chief Scientific Officer Danny Villeneuve appointed Chief Commercial Officer Terrie Kellmeyer, Ph.D., appointed Senior Vice President, Regulatory Affairs Christian Zapf, J.D., appointed General Counsel
Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions
SAN DIEGO, May 19, 2025 ( GLOBE NEWSWIRE ) -- Aardvark Therapeutics, Inc. ( Aardvark ) ( Nasdaq: AARD ) , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today ...
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Investing in promising companies before their stock prices soar is an excellent recipe for earning life-changing returns. However, with hundreds of companies vying for investors' attention, separating the wheat from the chaff can be challenging.Recognizing those corporations with long-term ...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis ...
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Late-breaking results from the open-label compensated MASH cirrhosis ( F4c ) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress 65% of patients with clinically significant portal hypertension ( CSPH ) at baseline moved into lower risk categories by year two
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ ( resmetirom ) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., May 10, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today announced positive two-year results from the ...
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected first-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
CONSHOHOCKEN, Pa., May 01, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reports first-quarter 2025 financial results and ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
CONSHOHOCKEN, Pa., April 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ: MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , announced today that it will release its first-quarter ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May ...
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., April 18, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH Dr. Taub's pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture? - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
High-rolling investors have positioned themselves bullish on Madrigal Pharmaceuticals MDGL, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday - ASP Isotopes ( NASDAQ:ASPI ) , ACM Research ( NASDAQ:ACMR )
U.S. stocks were mixed, with the Dow Jones falling over 150 points on Wednesday. Shares of Workday, Inc. WDAY rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter financial results.
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
Rezdiffra reduced liver stiffness by 6.7 kPa at two years, with 51% of patients showing ≥25% improvement in MASH cirrhosis. Madrigal posted a Q4 loss of $2.71 per share, beating estimates, with sales of $103.22 million surpassing the $98.56 million consensus.
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Why Madrigal Pharmaceuticals Stock Is Soaring Today
Shares of Madrigal Pharmaceuticals ( NASDAQ: MDGL ) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and full-year 2024 results before the market opened.Madrigal reported fourth-quarter revenue of ...
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ ( resmetirom ) in Patients with Compensated MASH Cirrhosis
CONSHOHOCKEN, Pa., Feb. 26, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( NASDAQ:MDGL ) , a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis ( MASH ) , today reported positive two-year results from the ...
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
CONSHOHOCKEN, Pa., Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( Nasdaq: MDGL ) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference - Madrigal Pharmaceuticals ( NASDAQ:MDGL )
CONSHOHOCKEN, Pa., Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. MDGL today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025
CONSHOHOCKEN, Pa., Feb. 12, 2025 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals, Inc. ( Nasdaq: MDGL ) announced today that it will release its fourth-quarter and full-year 2024 financial results on Wednesday, Feb. 26, 2025, prior to the open of the U.S. financial markets.
